Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model

Molecular Therapy

Volumn 12, Issue 4, 2005, Pages 634-643

  Bisanz, Kristen ^a   Yu, Jie ^a   Edlund, Magnus ^a   Spohn, Bill ^b   Hung, Mien Chie ^b   Chung, Leland W K ^a   Hsieh, Chia Ling ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Bioluminescence; Extracellular matrix; Integrins; Noninvasive imaging; Prostate cancer bone metastasis; Small interfering RNA

Indexed keywords

ANDROGEN; CD51 ANTIGEN; DRUG VEHICLE; INTEGRIN RECEPTOR; LIPOSOME; LUCIFERASE; MESSENGER RNA; SMALL INTERFERING RNA; VITRONECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BONE METASTASIS; CANCER CELL; CANCER INHIBITION; CELL ADHESION; CELL INTERACTION; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; DRUG TARGETING; ENCAPSULATION; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; NONVIRAL GENE THERAPY; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; GENE SILENCING; GENE THERAPY; HUMANS; INTEGRIN ALPHAV; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSTATIC NEOPLASMS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS; VITRONECTIN;

EID: 25144501954     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.05.012     Document Type: Article

References (49)

1. A. Jemal et al. Cancer statistics, 2003 CA Cancer J. Clin. 53 2003 5-26
2. M.A. Rubin et al. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer Clin. Cancer Res. 6 2000 1038-1045
3. J.C. Cheville et al. Metastatic prostate carcinoma to bone: Clinical and pathologic features associated with cancer-specific survival Cancer 95 2002 1028-1036
4. S.M. Albelda Role of integrins and other cell adhesion molecules in tumor progression and metastasis Lab. Invest. 68 1993 4-17
5. L.W. Chung and R. Davies Prostate epithelial differentiation is dictated by its surrounding stroma Mol. Biol. Rep. 23 1996 13-19
6. J.A. Varner P.C. Brooks and D.A. Cheresh The integrin alpha V beta 3: angiogenesis and apoptosis Cell. Adhes. Commun. 3 1995 367-374
7. C.H. Damsky and Z. Werb Signal transduction by integrin receptors for extracellular matrix: Cooperative processing of extracellular information Curr. Opin. Cell Biol. 4 1992 772-781
8. M.A. Schwartz and R.K. Assoian Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways J. Cell Sci. 114 2001 2553-2560
9. F.G. Giancotti and E. Ruoslahti Integrin signaling Science 285 1999 1028-1032
10. A.E. Aplin A.K. Howe and R.L. Juliano Cell adhesion molecules, signal transduction and cell growth Curr. Opin. Cell Biol. 11 1999 737-744
11. D.Q. Zheng A.S. Woodard M. Fornaro G. Tallini and L.R. Languino Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway Cancer Res. 59 1999 1655-1664
12. M. Edlund et al. Integrin expression and usage by prostate cancer cell lines on laminin substrata Cell Growth Differ. 12 2001 99-107
13. P.C. Brooks R.A. Clark and D.A. Cheresh Requirement of vascular integrin alpha v beta 3 for angiogenesis Science 264 1994 569-571
14. P.C. Brooks et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Cell 79 1994 1157-1164
15. P.C. Brooks et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin J. Clin. Invest. 96 1995 1815-1822
16. V. Lecrone W. Li R.E. Devoll C. Logothetis and M.C. Farach-Carson Calcium signals in prostate cancer cells: Specific activation by bone-matrix proteins Cell Calcium 27 2000 35-42
17. C.R. Cooper C.H. Chay and K.J. Pienta The role of alpha(v)beta(3) in prostate cancer progression Neoplasia 4 2002 191-194
18. S. De et al. Molecular pathway for cancer metastasis to bone J. Biol. Chem. 278 2003 39044-39050
19. N. Reinmuth et al. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice Cancer Res. 63 2003 2079-2087
20. O. Stoeltzing et al. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice Int. J. Cancer 104 2003 496-503
21. C.C. Kumar et al. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist Cancer Res. 61 2001 2232-2238
22. C. Van et al. Waes Effects of the novel alphav integrin antagonist SM256 and cis-platinum on growth of murine squamous cell carcinoma PAM LY8 Int. J. Oncol. 16 2000 1189-1195
23. J.D. Raguse H.J. Gath J. Bier H. Riess and H. Oettle Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour Oral. Oncol. 40 2004 228-230
24. MedImmune initiates phase I/II clinical study with Vitaxin Expert Rev. Anticancer Ther. 1 2001 166
25. P.Y. Lu F.Y. Xie and M.C. Woodle siRNA-mediated antitumorigenesis for drug target validation and therapeutics Curr. Opin. Mol. Ther. 5 2003 225-234
26. N.R. Wall and Y. Shi Small RNA: Can RNA interference be exploited for therapy? Lancet 362 2003 1401-1403
27. C.L. Hsieh V.F. Pang D.S. Chen and L.H. Hwang Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: Implications for cytotoxic T lymphocyte responses and tumor burdens Hum. Gene Ther. 8 1997 1843-1854
28. Y. Zou et al. Systemic tumor suppression by the proapoptotic gene bik Cancer Res. 62 2002 8-12
29. F. Jin Z. Xie C.J. Kuo L.W. Chung and C.L. Hsieh Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy Cancer Gene Ther. 12 2005 257-267
30. L.M. Kalikin et al. In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice Cancer Biol. Ther. 2 2003 656-660
31. N. Rubio M.M. Villacampa N. El Hilali and J. Blanco Metastatic burden in nude mice organs measured using prostate tumor PC-3 cells expressing the luciferase gene as a quantifiable tumor cell marker Prostate 44 2000 133-143
32. R.L. Juliano and J.A. Varner Adhesion molecules in cancer: The role of integrins Curr. Opin. Cell Biol. 5 1993 812-818
33. J.A. Nemeth et al. Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases Clin. Exp. Metastasis 20 2003 413-420
34. J.E. Bartsch E.D. Staren and H.E. Appert Adhesion and migration of extracellular matrix-stimulated breast cancer J. Surg. Res. 110 2003 287-294
35. D.I. Leavesley G.D. Ferguson E.A. Wayner and D.A. Cheresh Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen J. Cell Biol. 117 1992 1101-1107
36. E. Putz et al. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: Establishment of working models for human micrometastases Cancer Res. 59 1999 241-248
37. B.L. Bader H. Rayburn D. Crowley and R.O. Hynes Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins Cell 95 1998 507-519
38. V.W. Engleman et al. A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo J. Clin. Invest. 99 1997 2284-2292
39. P.A. Burke et al. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts Cancer Res. 62 2002 4263-4272
40. J.A. Posey et al. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer Cancer Biother. Radiopharm. 16 2001 125-132
41. B.P. Eliceiri Integrin and growth factor receptor crosstalk Circ. Res. 89 2001 1104-1110
42. J.A. Varner and D.A. Cheresh Integrins and cancer Curr. Opin. Cell Biol. 8 1996 724-730
43. B.P. Eliceiri and D.A. Cheresh Adhesion events in angiogenesis Curr. Opin. Cell Biol. 13 2001 563-568
44. U.N. Verma R.M. Surabhi A. Schmaltieg C. Becerra and R.B. Gaynor Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells Clin. Cancer Res. 9 2003 1291-1300
45. P.Y. Chien et al. Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo Cancer Gene Ther. 12 2005 321-328
46. S. Filleur et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth Cancer Res. 63 2003 3919-3922
47. Y. Zhang et al. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer Clin. Cancer Res. 10 2004 3667-3677
48. R.M. Schiffelers et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle Nucleic Acids Res. 32 2004 e149
49. C.L. Hsieh T.A. Gardner L. Miao G. Balian and L.W. Chung Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells Cancer Gene Ther. 11 2004 148-155